- Home
- ORGN vs NVCT Comparison
ORGN vs NVCT Comparison
Compare ORGN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- NVCT
- Stock Information
- Founded
- ORGN 2008
- NVCT 2020
- Country
- ORGN United States
- NVCT United States
- Employees
- ORGN N/A
- NVCT N/A
- Industry
- ORGN Major Chemicals
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- ORGN Industrials
- NVCT Health Care
- Exchange
- ORGN Nasdaq
- NVCT Nasdaq
- Market Cap
- ORGN 124.1M
- NVCT 119.4M
- IPO Year
- ORGN N/A
- NVCT 2022
- Fundamental
- Price
- ORGN $1.40
- NVCT $8.16
- Analyst Decision
- ORGN Strong Buy
- NVCT Strong Buy
- Analyst Count
- ORGN 1
- NVCT 1
- Target Price
- ORGN $3.00
- NVCT $21.00
- AVG Volume (30 Days)
- ORGN 675.5K
- NVCT 147.2K
- Earning Date
- ORGN 11-07-2024
- NVCT 11-06-2024
- Dividend Yield
- ORGN N/A
- NVCT N/A
- EPS Growth
- ORGN N/A
- NVCT N/A
- EPS
- ORGN N/A
- NVCT N/A
- Revenue
- ORGN $34,061,000.00
- NVCT N/A
- Revenue This Year
- ORGN $10.62
- NVCT N/A
- Revenue Next Year
- ORGN $175.99
- NVCT N/A
- P/E Ratio
- ORGN N/A
- NVCT N/A
- Revenue Growth
- ORGN 295.97
- NVCT N/A
- 52 Week Low
- ORGN $0.44
- NVCT $5.85
- 52 Week High
- ORGN $1.90
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- ORGN 45.07
- NVCT 62.26
- Support Level
- ORGN $1.34
- NVCT $7.20
- Resistance Level
- ORGN $1.50
- NVCT $9.07
- Average True Range (ATR)
- ORGN 0.07
- NVCT 0.59
- MACD
- ORGN -0.01
- NVCT 0.10
- Stochastic Oscillator
- ORGN 35.00
- NVCT 60.62
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.